13F Holdings
中文EN

IVVD Invivyd, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1832038 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.3%
TTM net income YoY-117.7%
TTM EPS YoY15.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-224.4%
Net margin-214.8%
FCF margin-221.0%
EBITDA margin—

Returns

ROE-107.0%
ROA-80.7%
ROIC (approx.)-668.6%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets18.2%
Debt / equity0.00x
Current ratio5.51x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.2%
Payout ratio—
Capex / revenue3.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$53.43M$25.38M$0——
R&D expense$38.31M$137.25M$158.66M$179.21M$182.89M
SG&A expense$66.93M$63.39M$49.12M$47.04M$36.52M
Operating income-$55.56M-$176.88M-$212.76M-$248.03M-$226.91M
Income tax$0$0$0$0$0
Net income-$52.49M-$169.93M-$198.64M-$241.32M-$226.79M
EBITDA——-$212.28M-$247.99M-$226.91M
EPS (basic)-0.30-1.43-1.81-2.23-5.32
EPS (diluted)-0.30-1.43-1.81-2.23-5.32
Weighted avg. shares (diluted)172.21M118.56M109.53M108.27M42.62M
Balance sheet
Cash & equivalents$226.69M$69.35M$200.64M$92.08M$542.22M
Receivables$13.92M$10.91M$0——
Inventory—$25.91M$0——
Current assets$247.47M$100.68M$224.88M$376.92M$616.71M
PP&E, net$1.36M$1.51M$1.90M$2.28M$83,000
Total assets$276.88M$129.51M$229.18M$383.17M$620.09M
Current liabilities$34.16M$61.98M$50.29M$25.03M$62.06M
Total liabilities$35.34M$61.98M$51.71M$27.20M$62.07M
Shareholders' equity$241.54M$67.54M$177.47M$355.97M$558.02M
Shares outstanding281.99M119.84M110.16M109.04M110.78M
Cash flow statement
Operating cash flow-$58.13M-$170.49M-$173.16M-$219.99M-$184.74M
Capital expenditure$155,000$140,000$615,000$1.71M$84,000
Free cash flow-$58.29M-$170.63M-$173.78M-$221.69M-$184.82M
Investing cash flow-$155,000-$140,000$280.68M-$230.67M-$50.71M
Financing cash flow$215.63M$39.33M$1.04M$506,000$662.68M
Depreciation & amortization——$480,000$41,000$1,000
Stock-based compensation$11.64M$19.79M$18.68M$21.65M$17.76M
Share buybacks—$0$1,000$4,000$0

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.